Skip to content

Markers of Inflammation and Lung Recovery in ECMO Patients for PPHN

A Feasibility Study to Consider the Relationship Between Markers of Red Cell Damage, Inflammation and the Recovery Process of Newborns Requiring Extracorporeal Membrane Oxygenation (ECMO) for Persistent Pulmonary Hypertension of the Newborn (PPHN): Mi-ECMO

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02940327
Acronym
Mi-ECMO
Enrollment
24
Registered
2016-10-20
Start date
2016-02-19
Completion date
2017-07-10
Last updated
2020-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Persistent Pulmonary Hypertension of the Newborn

Keywords

ECMO, PPHN, Pulmonary Hypertension of the Newborn, Markers of inflammation, Mi-Ecmo

Brief summary

Respiratory failure in newborns is common and has high rates of death. Where conventional intensive care strategies have failed, newborn children are referred to treatment with Extra- Corporeal Membrane Oxygenation (ECMO). This involves connecting children via large bore cannulas placed in their heart and major blood vessels to an artificial lung that adds oxygen to their blood and removes waste gases (carbon dioxide). Although this treatment saves lives, it still has some limitations. In particular, severe complications like bleeding, or damage to the kidneys can occur. These complications can lead to death in some cases and long-term disability in others. Based on ongoing research in adults and children undergoing cardiac surgery the investigators have identified a new process that may underlie some of the complications observed in ECMO. The investigators have noted that when transfused blood is infused in an ECMO circuit, this results in the accelerated release of substances from the donor cells that cause organ damage; at least in adults. There are treatments that can reverse this process. Before the investigators explore whether these treatments should be used in newborn children on ECMO, the investigators must first demonstrate that they can measure the complex inflammatory processes that occur in these critically ill children. The investigators therefore propose to conduct a feasibility study to identify the practical issues and challenges that would need to be overcome in order to perform a successful trial in this high-risk population.

Detailed description

The primary hypothesis is that damage to red blood cells by the exposure to the ECMO circuit will result in inflammatory responses that mitigate against successful weaning from Extra-Corporeal Membrane Oxygenation (ECMO) for Persistent Pulmonary Hypertension of the Newborn (PPHN). The secondary hypothesis are: 1. Damage to red cells will result in platelet, leukocyte and endothelial activation. 2. Markers of platelet, endothelial and leukocyte activation are indicators of lung inflammation and injury severity and hence lung recovery. 3. Markers of platelet, endothelial and leukocyte activation are indicators of kidney injury severity and hence acute kidney injury. 4. The level of oxidative stress will correlate with type shifts in pulmonary macrophages, tissue iron deposition and organ injury. 5. Ability to raise anti-oxidative response, measured by Heme Oxigenase-1 (HMOX 1) expression, will correlate with shorter intubation times and less severe kidney and lung injury. 6. Granulocyte and platelets activation are secondary to rising redox potential and the levels of activation will correlate with longer intubation times and more severe organ injury. 7. Markers of anti-oxidative response, platelet, endothelial and leukocyte activation, as well as oxidative stress levels have diagnostic and prognostic utility for the prediction of key clinical events including delayed time to recovery, acute kidney injury in paediatric patients undergoing Extra-Corporeal Membrane Oxygenation (ECMO) for Persistent Pulmonary Hypertension of the Newborn (PPHN). This is a pilot feasibility study that will establish the following: 1. Recruitment rates and patient flows for 24 patients specified as the target population for the feasibility study 2. Withdrawal rate, and completeness of follow-up and data collection in a paediatric population at high risk for death and major morbidity 3. The proportions (categorical data) and variance (continuous data) for the primary and secondary outcomes of interest. These will be used to model the sample sizes and outcomes that may be used in a definitive study 4. Perceptions of family members whose children participate in the study as to the appropriateness of the screening and consent process

Interventions

None listed

Sponsors

University Hospitals, Leicester
CollaboratorOTHER
Heart Link Children's Charity
CollaboratorOTHER
British Heart Foundation
CollaboratorOTHER
University of Leicester
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 30 Days
Healthy volunteers
No

Inclusion criteria

1. Patients with a diagnosis of PPHN 2. Patients that require ECMO support as determined by the ECMO team 3. Patients aged less than 30 days 4. Emergency consent obtained within 12 hours from cannulation, and ultimately full consent

Exclusion criteria

1. PPHN is caused by a congenital heart pathology 2. ECMO is required for a congenital heart disease 3. Lack of consent

Design outcomes

Primary

MeasureTime frameDescription
CD16/4112 hours after ECMO commencementChange of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry.
CD14/4112 hours after ECMO commencementChange of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry.
CD64/16312 hours after ECMO commencementChange of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry.

Secondary

MeasureTime frameDescription
Heart Injury as Determined by Serum Troponin Levels12 hours after ECMO commencementClinical and biochemical markers of organ failure
Change of Serum Haemoglobin LevelsbaselineClinical and biochemical markers of organ failure
Number of Participants Requiring Non Red Cell Transfusion24 hours after ECMO is discontinuedClinical and biochemical markers of organ failure
Allogenic Red Cell Transfusion Volume24 hours after ECMO is discontinuedClinical and biochemical markers of organ failure
Duration on ECMO> 7 days or did not survive to dischargeClinical and biochemical markers of organ failure
Number of Participants With Acute Kidney Injury>7 days or did not survive to dischargeClinical and biochemical markers of organ failure

Countries

United Kingdom

Participant flow

Participants by arm

ArmCount
1 - Observational Case-Controls
Observational Case-Controls.
24
Total24

Baseline characteristics

Characteristic1 - Observational Case-Controls
Age, Categorical
<=18 years
24 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
0 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
24 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Gestational age40.6 weeks
STANDARD_DEVIATION 2.6
Sex: Female, Male
Female
11 Participants
Sex: Female, Male
Male
13 Participants
Weight at birth3.2 kilograms

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
3 / 24
other
Total, other adverse events
1 / 24
serious
Total, serious adverse events
3 / 24

Outcome results

Primary

CD14/41

Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry.

Time frame: 24 hours after ECMO commencement

ArmMeasureValue (MEAN)Dispersion
7+ DaysCD14/413.02 percentage changeStandard Deviation 2.39
<7 DaysCD14/410.38 percentage changeStandard Deviation 3.48
Primary

CD14/41

Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry.

Time frame: 72 hours after ECMO commencement

ArmMeasureValue (MEAN)Dispersion
7+ DaysCD14/410.72 percentage changeStandard Deviation 4.65
<7 DaysCD14/410.59 percentage changeStandard Deviation 2.73
Primary

CD14/41

Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry.

Time frame: 24 hours after ECMO decannulation

ArmMeasureValue (MEAN)Dispersion
7+ DaysCD14/411.01 percentage changeStandard Deviation 3.03
<7 DaysCD14/410.40 percentage changeStandard Deviation 4.58
Primary

CD14/41

Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry.

Time frame: 12 hours after ECMO commencement

ArmMeasureValue (MEAN)Dispersion
7+ DaysCD14/411.5 percentage changeStandard Deviation 3.37
<7 DaysCD14/410.84 percentage changeStandard Deviation 2.97
Primary

CD14/41

Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry.

Time frame: 48 hours after ECMO commencement

ArmMeasureValue (MEAN)Dispersion
7+ DaysCD14/410.29 percentage changeStandard Deviation 4.51
<7 DaysCD14/410.27 percentage changeStandard Deviation 5.78
Primary

CD16/41

Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry.

Time frame: 24 hours after ECMO commencement

ArmMeasureValue (MEAN)Dispersion
7+ DaysCD16/413.11 percentage changeStandard Deviation 1.9
<7 DaysCD16/410.64 percentage changeStandard Deviation 3.26
Primary

CD16/41

Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry.

Time frame: 48 hours after ECMO commencement

ArmMeasureValue (MEAN)Dispersion
7+ DaysCD16/410.73 percentage changeStandard Deviation 3.86
<7 DaysCD16/410.4 percentage changeStandard Deviation 4.3
Primary

CD16/41

Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry.

Time frame: 72 hours after ECMO commencement

ArmMeasureValue (MEAN)Dispersion
7+ DaysCD16/411.55 percentage changeStandard Deviation 3.37
<7 DaysCD16/410.93 percentage changeStandard Deviation 1.99
Primary

CD16/41

Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry.

Time frame: 24 hours after decannulation

ArmMeasureValue (MEAN)Dispersion
7+ DaysCD16/411.56 percentage changeStandard Deviation 2.27
<7 DaysCD16/410.6 percentage changeStandard Deviation 3.98
Primary

CD16/41

Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry.

Time frame: 12 hours after ECMO commencement

ArmMeasureValue (MEAN)Dispersion
7+ DaysCD16/411.90 percent changeStandard Deviation 3.52
<7 DaysCD16/411.13 percent changeStandard Deviation 3.03
Primary

CD64/163

Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry.

Time frame: 24 hours after ECMO commencement

ArmMeasureValue (MEAN)Dispersion
7+ DaysCD64/1637.34 percentage changeStandard Deviation 5.13
<7 DaysCD64/1631.89 percentage changeStandard Deviation 5.87
Primary

CD64/163

Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry.

Time frame: 24 hours after decannulation

ArmMeasureValue (MEAN)Dispersion
7+ DaysCD64/1633.2 percentage changeStandard Deviation 3.55
<7 DaysCD64/1632.27 percentage changeStandard Deviation 2.89
Primary

CD64/163

Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry.

Time frame: 72 hours after ECMO commencement

ArmMeasureValue (MEAN)Dispersion
7+ DaysCD64/1633.31 percentage changeStandard Deviation 3.39
<7 DaysCD64/1631.9 percentage changeStandard Deviation 3.86
Primary

CD64/163

Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry.

Time frame: 12 hours after ECMO commencement

ArmMeasureValue (MEAN)Dispersion
7+ DaysCD64/1638.7 percentage changeStandard Deviation 2.52
<7 DaysCD64/1634.65 percentage changeStandard Deviation 2.81
Primary

CD64/163

Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry.

Time frame: 48 hours after ECMO commencement

ArmMeasureValue (MEAN)Dispersion
7+ DaysCD64/1633.26 percentage changeStandard Deviation 4.15
<7 DaysCD64/1630.92 percentage changeStandard Deviation 2.52
Secondary

Allogenic Red Cell Transfusion Volume

Clinical and biochemical markers of organ failure

Time frame: 24 hours after ECMO is discontinued

ArmMeasureValue (MEAN)Dispersion
7+ DaysAllogenic Red Cell Transfusion Volume289.6 mlStandard Deviation 241
<7 DaysAllogenic Red Cell Transfusion Volume479.2 mlStandard Deviation 268.2
Secondary

Change of Serum Haemoglobin Levels

Clinical and biochemical markers of organ failure

Time frame: 24 hours after decannulation

ArmMeasureValue (MEAN)Dispersion
7+ DaysChange of Serum Haemoglobin Levels109.25 g/LStandard Deviation 11.44
<7 DaysChange of Serum Haemoglobin Levels110.23 g/LStandard Deviation 12.15
Secondary

Change of Serum Haemoglobin Levels

Clinical and biochemical markers of organ failure

Time frame: baseline

ArmMeasureValue (MEAN)Dispersion
7+ DaysChange of Serum Haemoglobin Levels151.5 g/LStandard Deviation 33
<7 DaysChange of Serum Haemoglobin Levels145.4 g/LStandard Deviation 41.5
Secondary

Change of Serum Haemoglobin Levels

Clinical and biochemical markers of organ failure

Time frame: 12 hours after ECMO commencement

ArmMeasureValue (MEAN)Dispersion
7+ DaysChange of Serum Haemoglobin Levels109.64 g/LStandard Deviation 20.81
<7 DaysChange of Serum Haemoglobin Levels112.07 g/LStandard Deviation 16.33
Secondary

Change of Serum Haemoglobin Levels

Clinical and biochemical markers of organ failure

Time frame: 24 hours after ECMO commencement

ArmMeasureValue (MEAN)Dispersion
7+ DaysChange of Serum Haemoglobin Levels114.30 g/LStandard Deviation 11.92
<7 DaysChange of Serum Haemoglobin Levels109.43 g/LStandard Deviation 24.52
Secondary

Change of Serum Haemoglobin Levels

Clinical and biochemical markers of organ failure

Time frame: 48 hours after ECMO commencement

ArmMeasureValue (MEAN)Dispersion
7+ DaysChange of Serum Haemoglobin Levels112.56 g/LStandard Deviation 9.14
<7 DaysChange of Serum Haemoglobin Levels113.08 g/LStandard Deviation 6.32
Secondary

Change of Serum Haemoglobin Levels

Clinical and biochemical markers of organ failure

Time frame: 72 hours after ECMO commencement

ArmMeasureValue (MEAN)Dispersion
7+ DaysChange of Serum Haemoglobin Levels112.90 g/LStandard Deviation 7.65
<7 DaysChange of Serum Haemoglobin Levels109.89 g/LStandard Deviation 3.79
Secondary

Duration on ECMO

Clinical and biochemical markers of organ failure

Time frame: > 7 days or did not survive to discharge

ArmMeasureValue (MEDIAN)
7+ DaysDuration on ECMO292 hours
<7 DaysDuration on ECMO80 hours
Secondary

Heart Injury as Determined by Serum Troponin Levels

Clinical and biochemical markers of organ failure

Time frame: 72 hours after ECMO commencement

ArmMeasureValue (MEAN)Dispersion
7+ DaysHeart Injury as Determined by Serum Troponin Levels5.51 ng/mlStandard Deviation 2.03
<7 DaysHeart Injury as Determined by Serum Troponin Levels5.88 ng/mlStandard Deviation 2.09
Secondary

Heart Injury as Determined by Serum Troponin Levels

Clinical and biochemical markers of organ failure

Time frame: 24 hours after decannulation

ArmMeasureValue (MEAN)Dispersion
7+ DaysHeart Injury as Determined by Serum Troponin Levels9.54 ng/mlStandard Deviation 1.39
<7 DaysHeart Injury as Determined by Serum Troponin Levels7.44 ng/mlStandard Deviation 1.41
Secondary

Heart Injury as Determined by Serum Troponin Levels

Clinical and biochemical markers of organ failure

Time frame: 12 hours after ECMO commencement

ArmMeasureValue (MEAN)Dispersion
7+ DaysHeart Injury as Determined by Serum Troponin Levels7.89 ng/mlStandard Deviation 1.17
<7 DaysHeart Injury as Determined by Serum Troponin Levels6.96 ng/mlStandard Deviation 1.14
Secondary

Heart Injury as Determined by Serum Troponin Levels

Clinical and biochemical markers of organ failure

Time frame: 48 hours after ECMO commencement

ArmMeasureValue (MEAN)Dispersion
7+ DaysHeart Injury as Determined by Serum Troponin Levels2.13 ng/mlStandard Deviation 1.14
<7 DaysHeart Injury as Determined by Serum Troponin Levels1.81 ng/mlStandard Deviation 1.28
Secondary

Heart Injury as Determined by Serum Troponin Levels

Clinical and biochemical markers of organ failure

Time frame: 24 hours after ECMO commencement

ArmMeasureValue (MEAN)Dispersion
7+ DaysHeart Injury as Determined by Serum Troponin Levels3.71 ng/mlStandard Deviation 1.54
<7 DaysHeart Injury as Determined by Serum Troponin Levels3.11 ng/mlStandard Deviation 1.62
Secondary

Number of Participants Requiring Non Red Cell Transfusion

Clinical and biochemical markers of organ failure

Time frame: 24 hours after ECMO is discontinued

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
7+ DaysNumber of Participants Requiring Non Red Cell Transfusion10 Participants
<7 DaysNumber of Participants Requiring Non Red Cell Transfusion10 Participants
Secondary

Number of Participants With Acute Kidney Injury

Clinical and biochemical markers of organ failure

Time frame: >7 days or did not survive to discharge

ArmMeasureValue (NUMBER)
7+ DaysNumber of Participants With Acute Kidney Injury3 participants
<7 DaysNumber of Participants With Acute Kidney Injury0 participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026